

\$4

1c872 U.S. PTO
10/071485
02/07/02

EXPRESS MAIL MAILING LABEL	
NUMBER EL 831787862 US	
DATE OF DEPOSIT	<u>February 7, 2002</u>
I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: BOX PATENT APPLICATION, Commissioner for Patents, Washington D.C. 20231.	
<u>Paula S. Linkhart</u> Paula S. Linkhart	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Marie-Ange BUYSE
Erwin SABLON

Serial No.:

Filed:

For: **INTERFERON-GAMMA-BINDING
MOLECULES FOR TREATING SEPTIC
SHOCK, CACHEXIA, IMMUNE
DISEASES AND SKIN DISORDERS**

§
§
§ Group Art Unit:
§
§ Examiner:
§
§ Atty. Dkt. No.: **INNS015—1**
11362.0015.DVUS01
§
§
§
§
§

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information is, or is considered to be, prior art or material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from **Deposit Account No. 01-2508/11362.0015.DVUS01**.

This application is a divisional application of Serial No. 09/485,737, filed February 14, 2000 and is relied upon for an earlier filing date under 35 U.S.C. 120. In accordance with 37 C.F.R. § 1.98(d), copies of the listed documents B1 and C1-C13 are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/485,737.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Patricia A. Kammerer
Reg. No. 29,775
Attorney for Assignee
INNOGENETICS N.V.

Howrey Simon Arnold & White, LLP
750 Bering Drive
Houston, TX 77057-2198
(713) 787-1400

Date: February 7, 2002

Form PTO-1449 (modified)		Atty. Docket No. INNS:015--1	Serial No.
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Marie-Ange Buyse; Erwin Sablon	
		Filing Date: Herewith	Group:
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

14872 U.S. P.T.P.
10/07/1485
02/07/02

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 92 11018 A	07/09/92	WIPO	A61K	35/14	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Froyen, G. et al., <u>Biotherapy</u> 10:49-57 (1997)
	C2	Leist, T. et al., <u>Journal of Virology</u> 63:2813-2819 (1989)
	C3	Zhu, Z. et al., <u>Proceedings of the American Association for Cancer Research</u> 37:468 (1996)
	C4	Iliades, P. et al., <u>FEBS Letters</u> 409:437-441 (1997)
	C5	Adams, G.P. et al., <u>Cancer Research</u> 53:4026-4034 (1993)
	C6	Rheinnecker, M. et al., <u>Journal of Immunology</u> 157:2989-2997 (1996)
	C7	Paul, <u>Fundamental Immunology</u> , chap 8, p. 242, Raven Press, NY (1993)
	C8	Pack, et al., <u>Journal of Molecular Biology</u> 246:28-34 (1995)
	C9	Froyen, et al., <u>Molecular Immunology</u> 30:805-812 (1993)
	C10	Kortt, et al., <u>Protein Engineering</u> 10:423-433 (1997)
	C11	Billiau, et al., <u>European Journal of Immunology</u> 17:1851-54 (1987)
	C12	Tersikh, et al., <u>Proceedings of the National Academy of Sciences USA</u> , 94:1663-1668 (1997)
	C13	Coloma, et al., <u>Nature Biotechnology</u> 15:159-163 (1997)

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)